- GHO partnering with existing management team to accelerate global growth
- ClearView positioned as market leader in an industry experiencing strong tailwinds
- Management to pursue international markets and broaden service offering, leveraging GHO’s unparalleled sector expertise
London, UK – Global Healthcare Opportunities, or GHO Capital Partners LLP, the European specialist investor in global healthcare, and the founding partners of ClearView Healthcare Partners, announce a majority recapitalisation of ClearView Healthcare Partners (“ClearView”), the leading life sciences strategic consultancy supporting Pharma and Biotech sponsors globally.
Headquartered in Boston and with offices in New York, San Francisco, London and Zurich, ClearView is known for combining its deep and diversified therapeutic expertise with business insights to deliver actionable recommendations to its customers in support of growth and innovation strategy. ClearView supports drug sponsors throughout the development and commercialisation process as well as guides overall approaches to clinical and commercial portfolio development. ClearView services a wide range of market leading innovators across the Big Pharma/Biopharma, Diagnostics, MedTech, and life science services/tools segments.
Led by its founders, Rich Mynahan, Steve Chao and Kevin Richard, alongside a world-class leadership team, ClearView is well positioned to enhance its market-leading position within life sciences consulting, an industry exhibiting accelerating secular growth. Against a backdrop of industry fragmentation, the company will significantly benefit from GHO’s resources, expertise and global reach in building its European practice and driving geographic expansion via M&A.
ClearView is set to continue driving significant organic growth, cross selling emerging solutions including data analytics and pricing & market access to expand an existing client base while leveraging relationships to broaden capabilities across the small and mid-cap life sciences.
The investment follows the announcement of GHO Capital III, in July 2021, with over €2 billion of capital available to invest, the addition of new team hires and the opening of an office on the East Coast, US in support of GHO’s network of North American companies.
The Partners at GHO Capital, said, “We are delighted to have the opportunity to partner with the ClearView team. Operating within a highly fragmented market, ClearView is a best-in-class consultancy within the life sciences space. We believe GHO, with its strong sector expertise, is uniquely positioned to build on ClearView’s strong track record and reputation. We look forward to supporting the business in driving international expansion and building out its domain expertise to deliver strategically critical insights to its Biopharma customer base.”
The Founders at ClearView Healthcare Partners, said, “We are excited to be working with GHO given their extensive healthcare expertise and experience in geographic expansion across Europe and the US. We believe GHO is the right partner for ClearView as we look to new markets and drive the expansion and growth of the company to its next level. We thank RLH Equity Partners for their support in contributing to ClearView’s position as a market leader in the life sciences consulting sector.”
GHO invested an undisclosed amount in ClearView from RLH Equity Partners for a majority stake, with founding partners and leadership retaining a material ownership position in the firm.
Ropes & Gray acted as legal advisor to GHO, Marwood as commercial advisor, Deloitte LLP as financial, tax and debt advisor, Bridgehouse Advisors as ESG advisor and Hays as insurance advisor.
Clearsight Advisors and Houlihan Lokey acted as co-strategic advisors to ClearView, Winston & Strawn and Foley Hoag LLP acted as legal advisors and RSM US LLP as financial and tax advisor.